Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Sei Shu"'
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Genetic alterations, including mutation of epidermal growth factor receptor or v-Ki-ras2 kirsten rat sarcoma viral oncogene homolog and fusion of anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET), or v-ros UR2 sarcoma vir
Externí odkaz:
https://doaj.org/article/ef64ea6b2ade4f5ba0135f660fd044ed
Autor:
Yoriko Yamashita-Kashima, Naoki Harada, Shigeki Yoshiura, Yasushi Yoshimura, Sei Shu, Takaaki Fujimura, Masahiro Osada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Trastuzumab emtansine (T-DM1) is the standard treatment in the current second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, a useful therapy after T-DM1 resistance has not been est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0847544a20f3eba7ad898f925f504b9f
https://doi.org/10.1007/s00280-020-04138-5
https://doi.org/10.1007/s00280-020-04138-5
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer
BMC Cancer
Background Genetic alterations, including mutation of epidermal growth factor receptor or v-Ki-ras2 kirsten rat sarcoma viral oncogene homolog and fusion of anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET), or v-ros UR2 sarcoma virus oncoge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e4a599b076e8c003bc823f3a428673
http://link.springer.com/article/10.1186/s12885-019-5527-2
http://link.springer.com/article/10.1186/s12885-019-5527-2
Autor:
YORIKO YAMASHITA-KASHIMA1, SEI SHU1, KEIGO YOROZU1, YOICHIRO MORIYA1, NAOKI HARADA1 haradanok@chugai-pharm.co.jp
Publikováno v:
Oncology Letters. Oct2017, Vol. 14 Issue 4, p4197-4205. 9p.
Publikováno v:
Oncology Letters
In a Phase III trial for HER2-positive breast cancer (the CLEOPATRA study), the triple-drug combination arm of pertuzumab plus trastuzumab plus docetaxel showed significantly longer progression-free survival and overall survival than did the trastuzu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcf0eff207e408aeaf11280ca02066a0
http://europepmc.org/articles/PMC5607650
http://europepmc.org/articles/PMC5607650
Autor:
Sei Shu, Yasuhiro Kodera, Naoki Harada, Yoriko Yamashita-Kashima, Mieko Yanagisawa, Hayao Nakanishi, Yasushi Yoshimura
Publikováno v:
Anti-cancer drugs. 31(3)
Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b72cfaf16677f7ecb8fecb2ef359c6b
https://pubmed.ncbi.nlm.nih.gov/31633500
https://pubmed.ncbi.nlm.nih.gov/31633500
Autor:
Hiroshi Saeki, Takeshi Wakasa, Eiji Oki, Sei Shu, Yoshinao Oda, Koji Ando, Makoto Iimori, Yoshihiko Maehara
Publikováno v:
Journal of Cell Science.
Chromosomal instability, one of the most prominent features of tumour cells, causes aneuploidy. Tetraploidy is thought to be an intermediate on the path to aneuploidy, but the mechanistic relationship between the two states is poorly understood. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f837a5bca9e359cddade33e6af7487a
https://doi.org/10.1242/jcs.231530
https://doi.org/10.1242/jcs.231530
Autor:
Yoriko Yamashita‑Kashima, Sei Shu, Masahiro Osada, Takaaki Fujimura, Shigeki Yoshiura, Naoki Harada, Yasushi Yoshimura
Publikováno v:
Cancer Chemother Pharmacol
Trastuzumab emtansine (T-DM1) is the standard treatment in the current second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, a useful therapy after T-DM1 resistance has not been established
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1596f6dda7fbdf1a9140d03ceec8277
https://doi.org/10.1007/s00280-020-04212-y
https://doi.org/10.1007/s00280-020-04212-y
Autor:
Hiroshi Saeki, Tomoko Jogo, Yoshihiko Maehara, Eiji Oki, Ryota Nakanishi, Makoto Iimori, Sei Shu
Publikováno v:
In vivo (Athens, Greece). 32(6)
Background It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. Materi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd0d59e0b3d83937c8380b8171b38967
https://pubmed.ncbi.nlm.nih.gov/30348707
https://pubmed.ncbi.nlm.nih.gov/30348707
Autor:
Kazunori Ishige, Toru Kawamoto, Masakazu Yamamoto, Shunichi Ariizumi, Nobuyuki Ishikura, Yoriko Yamashita-Kashima, Kunihiko Kurosaki, Junichi Shoda, Melanie B. Thomas, Sei Shu
Publikováno v:
Journal of Gastroenterology. 50:467-479
Pertuzumab is a humanized monoclonal antibody that binds to HER2 at an epitope that prevents HER2 from dimerizing with ligand-activated HER-family receptors. To assess the potential of pertuzumab as a new therapy, the expression status of HER family
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3fe10aba6a22402046d9c17e0479697
https://doi.org/10.1007/s00535-014-0984-5
https://doi.org/10.1007/s00535-014-0984-5